- Home
- AMC vs JANX Comparison
AMC vs JANX Comparison
Compare AMC & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMC | JANX |
|---|---|---|
| Founded | 1920 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 993.9M | 840.4M |
| IPO Year | 2007 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AMC | JANX |
|---|---|---|
| Price | $1.99 | $14.64 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 13 |
| Target Price | $2.03 | ★ $47.00 |
| AVG Volume (30 Days) | ★ 46.2M | 845.1K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,848,900,000.00 | $10,000,000.00 |
| Revenue This Year | $11.41 | N/A |
| Revenue Next Year | $5.18 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 4.57 | N/A |
| 52 Week Low | $0.93 | $12.12 |
| 52 Week High | $3.60 | $35.34 |
Technical Indicators
Market Signals| Indicator | AMC | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 50.40 | 59.43 |
| Support Level | $2.05 | $13.13 |
| Resistance Level | $2.34 | $15.49 |
| Average True Range (ATR) | 0.24 | 0.57 |
| MACD | -0.01 | 0.15 |
| Stochastic Oscillator | 27.42 | 84.78 |
Price Performance
Historical ComparisonAbout AMC AMC Entertainment Holdings Inc.
AMC Entertainment Holdings Inc is involved in the theatrical exhibition business. The company owns, operates, or has interests in theatres located in the United States and Europe. It provides amenities such as plush, power recliners, MacGuffins full bars, AMC Dine-In Theatres, and premium presentation. The company has identified two reportable segments and reporting units for its theatrical exhibition operations, U.S. markets and International markets. It derives key revenue from the U.S.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.